GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Qilian International Holding Group Ltd (NAS:QLI) » Definitions » Debt-to-EBITDA

Qilian International Holding Group (Qilian International Holding Group) Debt-to-EBITDA : -0.16 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Qilian International Holding Group Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Qilian International Holding Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.55 Mil. Qilian International Holding Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.03 Mil. Qilian International Holding Group's annualized EBITDA for the quarter that ended in Sep. 2023 was $-3.60 Mil. Qilian International Holding Group's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -0.16.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Qilian International Holding Group's Debt-to-EBITDA or its related term are showing as below:

QLI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.45   Med: 0.59   Max: 2.05
Current: -0.45

During the past 7 years, the highest Debt-to-EBITDA Ratio of Qilian International Holding Group was 2.05. The lowest was -0.45. And the median was 0.59.

QLI's Debt-to-EBITDA is ranked worse than
100% of 659 companies
in the Drug Manufacturers industry
Industry Median: 1.66 vs QLI: -0.45

Qilian International Holding Group Debt-to-EBITDA Historical Data

The historical data trend for Qilian International Holding Group's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qilian International Holding Group Debt-to-EBITDA Chart

Qilian International Holding Group Annual Data
Trend Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Debt-to-EBITDA
Get a 7-Day Free Trial 0.59 1.05 1.93 0.47 -0.45

Qilian International Holding Group Semi-Annual Data
Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.47 3.49 0.47 0.64 -0.16

Competitive Comparison of Qilian International Holding Group's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Qilian International Holding Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qilian International Holding Group's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Qilian International Holding Group's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Qilian International Holding Group's Debt-to-EBITDA falls into.



Qilian International Holding Group Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Qilian International Holding Group's Debt-to-EBITDA for the fiscal year that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.553 + 0.025) / -1.275
=-0.45

Qilian International Holding Group's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.553 + 0.025) / -3.602
=-0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Sep. 2023) EBITDA data.


Qilian International Holding Group  (NAS:QLI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Qilian International Holding Group Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Qilian International Holding Group's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Qilian International Holding Group (Qilian International Holding Group) Business Description

Traded in Other Exchanges
N/A
Address
Jiuquan Economic and Technological Development Zone, Gansu Province, Jiuquan, CHN, 735000
Qilian International Holding Group Ltd is a pharmaceutical and chemical company. The company is engaged in the development, manufacture, marketing, and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives products, heparin products, sausage casings, and fertilizers. It operates through three segments namely, Oxytetracycline and Licorice products and TCMD; Fertilizer; and Heparin products and Sausage casing. Oxytetracycline and Licorice products and TCMD segment generates majority of the revenue.

Qilian International Holding Group (Qilian International Holding Group) Headlines

From GuruFocus